ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced positive results from its marketing enabling clinical study of ANX-530 (vinorelbine emulsion). Pharmacokinetic equivalence, the primary endpoint of the study, was observed between ANX-530 and Navelbine(R), the reference product, in patients with advanced cancer potentially sensitive to vinorelbine. [click link for full article]